2013 Apr 15 Annual Report 2012 - Phosphagenics

Notes to the consolidated fi nancial statements
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
(e) Significant accounting judgements, estimates and assumptions (continued)
Development costs
An intangible asset arising from development expenditure on an internal project is recognised only when
Phosphagenics can demonstrate the technical feasibility of completing the intangible asset so that it will
be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset
will generate future economic benefi ts, the availability of resources to complete the development and
the ability to measure reliably the expenditure attributable to the intangible asset during its development.
Any expenditure capitalised is amortised over the period of expected future benefi t from the related project
on a straight line basis. The carrying value of capitalised developments costs not yet available for use
is tested for impairment annually at 31 December.
Certain development costs relate to patents which have fi nite lives. These costs are being amortised over
their remaining useful lives which ranges between 9 to 12 years.
(f) Cash and cash equivalents
Cash and short term deposits in the statement of fi nancial position comprise cash at bank and in hand
and short-term deposits with an original maturity of six months or less, that are readily convertible
to known amounts of cash and which are subject to an insignifi cant rate of change in value.
For the purposes of the consolidated statement of cash fl ows, cash and cash equivalents consist of cash
and cash equivalents as defi ned above, net of outstanding bank overdrafts.
(g) Provisions and employee benefits
General
79
Provisions are recognised when the Group has a present obligation (legal or constructive) as a result
of a past event, it is probable that an outfl ow of resources embodying economic benefi ts will be required
to settle the obligation and a reliable estimate can be made of the amount of the obligation.
When the Group expects some or all of a provision to be reimbursed, for example under an insurance
contract, the reimbursement is recognised as a separate asset but only when the reimbursement is
virtually certain. The expense relating to any provision is presented in the statement of comprehensive
income net of any reimbursement.
Provisions are measured at the present value of management’s best estimate of the expenditure required
to settle the present obligation at the reporting date. The discount rate used to determine the present
value refl ects the current market assessments of the time value of money and the risks specifi c to the
liability. The increase in the provision resulting from the passage of time is recognised in fi nance costs.
Employee leave benefits
Wages, salaries and, annual leave.
Liabilities for wages and salaries, including non-monetary benefi ts and annual leave expected to be settled
within twelve months of the reporting date are recognised in respect of employees’ services up to the
reporting date. They are measured at the amounts expected to be paid when the liabilities are settled.
Liabilities for non-accumulating sick leave are recognised when the leave is taken and are measured
at the rates paid or payable.
Long service leave
The liability for long service leave is recognised and measured as the present value of expected future
payments to be made in respect of services provided by employees up to the reporting date using the
projected unit credit method. Consideration is given to expected future wage and salary levels, experience
of employee departures, and periods of service. Expected future payments are discounted using market
yields at the reporting date on national government bonds with terms to maturity and currencies that
match, as closely as possible, the estimated future cash outfl ows.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS